Observation of Long-term Effects on Endometrium and Uterine Fibroids in Women With Ulipristal Acetate Therapy
Long-term Observation of Symptomatic Women With Uterine Fibroids Who Have Been Treated With Ulipristal Acetate: Findings on Symptomatology, Morphological Structure, Endometrial Patterns
1 other identifier
observational
89
1 country
1
Brief Summary
A prospective observational study on italian women undergoing ulipristal acetate (uPa) therapy for symptomatic myomas and its impact on symptomatology and moreover on myomas architecture. We also evaluate changes in the endometrial pattern of selected women.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2018
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2018
CompletedFirst Submitted
Initial submission to the registry
May 21, 2019
CompletedFirst Posted
Study publicly available on registry
June 4, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 10, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
September 21, 2021
CompletedJanuary 18, 2023
January 1, 2023
2.7 years
May 21, 2019
January 14, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Dysmenhorrea (VAS score)
12 months
Endometrial thickess (mm)
12 months
Myoma's diameter (mm)
12 months
Secondary Outcomes (1)
Live birth rate (LBR)
12 months
Study Arms (1)
ulipristal acetate based therapy
Fertile women under ulipristal acetate treatment
Interventions
Evaluation of endometrial thickness; myoma size and volume
Eligibility Criteria
Italian fertile women who are eligible for conservative treatment for uterine fibroids
You may qualify if:
- number of myomas from 1 to 4
- heavy menstrual bleeding
- conservative treatment request
You may not qualify if:
- concurrent endometrial pathology
- post-menopausal status
- hepatic pathology
- endocrine or metabolic disorders
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli"
Naples, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Gaetano Riemma, MD
University of Campania Luigi Vanvitelli
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
May 21, 2019
First Posted
June 4, 2019
Study Start
November 1, 2018
Primary Completion
July 10, 2021
Study Completion
September 21, 2021
Last Updated
January 18, 2023
Record last verified: 2023-01